Finance

Beta
Lists
ALGS:NASDAQ
Aligos Therapeutics Inc
$5.50
-1.35%
(-0.075) 1D
Jun 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALGS...
Open
$5.63
High
$5.79
Low
$5.48
Mkt. cap
34.00M
Avg. vol.
109.12K
Volume
0.00
52-wk high
$13.69
52-wk low
$4.82
EPS
-$8.70
Beta
2.25
Shares outstanding
5.39M
No. of employees
82
Open
$5.63
High
$5.79
Low
$5.48
Mkt. cap
34.00M
Avg. vol.
109.12K
Volume
0.00
52-wk high
$13.69
52-wk low
$4.82
EPS
-$8.70
Beta
2.25
Shares outstanding
5.39M
No. of employees
82
News stories
From sources across the web
About Aligos Therapeutics Inc
CEO-
Employees82
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitealigos.com
Analyst ratings
Based on 4 analysts giving stock ratings to ALGS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ALGS in the last 3 months.
Highest
Current $5.50
$175.00 (+3,081.82%)
Average
$72.50 (+1,218.18%)
Lowest
$20.00 (+263.64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$50.00
+809.1%
06/03/2026
Daniel Brims
Lake Street
Buy
Maintained
$45.00
+718.2%
06/01/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$20.00
+263.6%
05/28/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
$20.00
+263.6%
05/21/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$175.00
+3,081.8%
05/08/2026
Anthea Li
Jefferies
Buy
Initiated
$48.00
+772.7%
03/19/2026
Unknown Analyst
Jefferies
Buy
Initiated
$48.00
+772.7%
03/19/2026
Michael Yee
UBS
Buy
Maintained
$20.00
+263.6%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
965.00K
741.00K
169.00K
2.83M
Cost of goods sold
13.98M
23.94M
17.04M
666.00K
Cost of revenue
13.98M
23.94M
17.04M
666.00K
Research and development expenses
-
-
-
22.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.56M
5.16M
4.94M
6.41M
Operating expense
5.56M
5.16M
4.94M
29.09M
Total operating expenses
19.53M
29.10M
21.98M
29.76M
Operating income
-18.57M
-28.36M
-21.81M
-26.93M
Other non operating income
2.49M
-3.50M
1.22M
4.07M
EBT including unusual items
-15.68M
-31.48M
-19.85M
-22.72M
EBT excluding unusual items
-15.68M
-31.48M
-19.85M
-22.72M
Income tax expense
185.00K
56.00K
30.00K
317.00K
Effective tax rate
-1.18%
-0.18%
-0.15%
-1.40%
Other operating expenses
-
-
-
-
Net income
-15.86M
-31.54M
-19.88M
-23.04M
Net profit margin
-1,643.83%
-4,256.01%
-11,763.91%
-814.13%
Earnings per share
-1.53
-3.04
-1.91
-2.21
Interest and investment income
396.00K
378.00K
548.00K
140.00K
Interest expense
-
-
-
-
Net interest expenses
396.00K
378.00K
548.00K
140.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.31M
-28.14M
-21.56M
-26.58M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ALGS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer